Cytotoxicity Assay: Overview of LDH, MTT, and ATP-Based Methods

Cytotoxicity assays are laboratory methods used to measure the loss of cell viability or the disruption of cellular function following exposure to test agents, drugs, or materials. These assays are essential for evaluating the biocompatibility of medical devices, screening pharmaceutical compounds, and assessing chemical toxicity in basic research and regulatory toxicology. The three most widely used approaches—LDH release, MTT reduction, and ATP quantification—each measure distinct cellular endpoints: membrane integrity (LDH), metabolic activity (MTT), and energy metabolism (ATP). The choice of assay depends on the cell type, the mechanism of toxicity being investigated, and the specific experimental context, as no single method is universally optimal for all applications.

At a Glance

Scientific Principle of Cytotoxicity Assays

Cytotoxicity testing is a cornerstone of modern toxicology, providing critical insight into how chemicals and drugs affect cell viability and function [1]. The fundamental principle underlying all cytotoxicity assays is that viable cells maintain specific biochemical and structural characteristics that are lost upon cell death. Different assays exploit these characteristics to distinguish living from dead cells.

The LDH release assay is based on the measurement of lactate dehydrogenase, a stable cytosolic enzyme present in virtually all mammalian cells. When the plasma membrane is compromised—as occurs during necrosis or late-stage apoptosis—LDH leaks into the surrounding culture medium. By measuring LDH activity in the supernatant using a coupled enzymatic reaction that converts NAD+ to NADH, which then reduces a tetrazolium salt to a colored formazan product, the extent of membrane damage can be quantified. This assay specifically detects loss of membrane integrity, which is a hallmark of necrotic cell death and secondary necrosis following apoptosis.

The MTT assay, named for the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, measures cellular metabolic activity. Viable cells contain NAD(P)H-dependent oxidoreductase enzymes, primarily located in mitochondria but also present in the cytosol and endoplasmic reticulum, that reduce MTT to insoluble purple formazan crystals. The amount of formazan produced is proportional to the number of metabolically active cells. This assay does not directly measure cell death but rather the metabolic capacity of the cell population, which correlates with viability under most conditions.

ATP-based assays rely on the principle that ATP is present in all metabolically active cells and is rapidly depleted upon cell death. The assay uses firefly luciferase, which catalyzes the oxidation of D-luciferin in the presence of ATP, magnesium ions, and molecular oxygen, producing light. The bioluminescent signal is directly proportional to ATP concentration, which in turn is proportional to the number of viable cells. This method is exceptionally sensitive because the luciferase reaction generates a strong signal from minute amounts of ATP.

Materials and Instrumentation Choices

Cell Culture Materials

All cytotoxicity assays require standard cell culture equipment: a Class II biological safety cabinet, a CO₂ incubator maintained at 37°C with 5% CO₂, and an inverted microscope for routine cell observation. For BSL-1 routine work, as specified in the safety boundary, cell lines should be well-characterized, non-pathogenic, and free from adventitious agents. Common choices include HeLa, HEK 293, NIH/3T3, or Vero cells, depending on the experimental question.

The choice of culture vessel depends on the assay format. For colorimetric assays (LDH and MTT), 96-well plates are standard because they allow simultaneous processing of multiple conditions and are compatible with plate readers. For ATP assays, white opaque 96-well plates are recommended to minimize well-to-well light cross-talk and maximize signal detection. Clear-bottom plates can be used if microscopic observation is also required, but white plates provide superior sensitivity for luminescence measurements.

Reagent Systems

For LDH assays, commercial kits are widely available and typically include a substrate mix containing lactate, NAD+, and a tetrazolium salt (e.g., INT or WST-1), along with a diaphorase or similar electron mediator. The choice of kit affects sensitivity and linear range. Some kits are optimized for low-serum conditions, while others include a lysis buffer for preparing maximum LDH release controls. The assay buffer should be prepared fresh and protected from light.

For MTT assays, MTT powder is dissolved in phosphate-buffered saline (PBS) at 5 mg/mL, filter-sterilized, and stored at -20°C protected from light. The solubilization solution, typically acidified isopropanol (0.1 N HCl in isopropanol) or dimethyl sulfoxide (DMSO), dissolves the formazan crystals for spectrophotometric measurement. Some commercial MTT kits provide ready-to-use solutions and solubilization reagents.

For ATP assays, commercial luciferase-based kits are strongly recommended because they contain optimized buffers, luciferase, and luciferin in stabilized formulations. These kits typically include a cell lysis buffer and an ATP-stabilizing agent. The choice of kit affects signal stability and sensitivity. Some kits are designed for high-throughput screening with extended signal half-life, while others prioritize maximum sensitivity for low cell numbers.

Instrumentation

Colorimetric assays (LDH and MTT) require a microplate reader capable of measuring absorbance at the appropriate wavelengths. For LDH, the typical measurement wavelength is 490–500 nm, with a reference wavelength of 600–650 nm to correct for background absorbance. For MTT, the measurement wavelength is 540–570 nm, with a reference wavelength of 630–690 nm. A plate reader with temperature control is advantageous for kinetic LDH measurements.

ATP assays require a luminometer, which can be a dedicated instrument or a plate reader equipped with luminescence detection capability. The luminometer must be capable of integrating the signal over a defined period (typically 0.1–1 second per well). Sensitivity specifications vary; instruments with photon-counting photomultiplier tubes provide the highest sensitivity, while CCD-based detectors are suitable for most applications.

Controls and Their Importance

Proper controls are essential for interpreting cytotoxicity assay results. The following controls should be included in every experiment:

Vehicle control: Cells treated with the same concentration of solvent (e.g., DMSO, ethanol, or culture medium) used to deliver the test compound. This control establishes baseline viability and accounts for any solvent-induced toxicity.

Positive control: Cells treated with a known cytotoxic agent. For general cytotoxicity, 0.1–1% Triton X-100 or 10–100 µM staurosporine are commonly used. The positive control confirms that the assay system can detect cytotoxicity and that reagents are functioning correctly.

Negative control: Untreated cells in complete culture medium. This control establishes the maximum viability signal for the assay.

Background control: Cell-free wells containing only culture medium and test compound. This control accounts for any background signal from the medium, serum, or test compound itself. For LDH assays, serum contains LDH, so the background control is particularly important.

Maximum LDH release control: For LDH assays, a set of wells containing cells treated with a lysis buffer (typically 1–2% Triton X-100) to release all intracellular LDH. This control defines 100% cytotoxicity and is used to calculate percent LDH release.

Cell number standard curve: For ATP assays, a standard curve using known numbers of viable cells is essential for converting luminescence values to cell numbers. This curve should be prepared fresh for each experiment because ATP content per cell can vary with culture conditions.

Conceptual Workflow

Step 1: Cell Preparation and Plating

Seed cells in 96-well plates at a density that ensures logarithmic growth throughout the experiment. The optimal seeding density depends on the cell type, growth rate, and assay duration. For most adherent cell lines, seed 5,000–20,000 cells per well for a 24-hour assay, or 1,000–5,000 cells per well for a 72-hour assay. Allow cells to attach and recover for 24 hours before treatment.

For suspension cells, seed directly in treatment medium at the desired density. Include a pre-incubation period of 2–4 hours to allow cells to equilibrate.

Step 2: Test Compound Exposure

Prepare serial dilutions of the test compound in culture medium. The concentration range should span at least four orders of magnitude, with at least six concentrations, to generate a reliable dose-response curve. Replace the culture medium with treatment medium, taking care not to disturb the cell monolayer. Include all controls on the same plate.

Incubate for the desired exposure period. Typical exposure times range from 24 to 72 hours, but shorter exposures (4–8 hours) may be appropriate for acute toxicity studies.

Step 3: Assay-Specific Procedures

For LDH assay: After the exposure period, transfer 50–100 µL of supernatant from each well to a fresh 96-well plate, being careful not to disturb the cell monolayer. Add an equal volume of LDH reaction mixture, incubate at room temperature in the dark for 30 minutes, and measure absorbance at 490–500 nm.

For MTT assay: After the exposure period, add 10–20 µL of MTT solution (5 mg/mL) to each well (final concentration 0.5 mg/mL). Incubate for 2–4 hours at 37°C. Remove the medium carefully, add 100–150 µL of solubilization solution, and incubate at 37°C with gentle shaking until formazan crystals are fully dissolved. Measure absorbance at 540–570 nm.

For ATP assay: After the exposure period, remove the culture medium and add cell lysis buffer according to the kit instructions. Alternatively, for suspension cells, add lysis buffer directly to the culture medium. Transfer the lysate to a white opaque plate if not already using one. Add luciferase reagent, mix gently, and measure luminescence within 5–30 minutes.

Step 4: Data Collection and Analysis

Calculate percent viability or cytotoxicity using the appropriate formula. For LDH assays, percent cytotoxicity = [(experimental LDH release - spontaneous LDH release) / (maximum LDH release - spontaneous LDH release)] × 100. For MTT and ATP assays, percent viability = (absorbance or luminescence of treated sample / absorbance or luminescence of vehicle control) × 100.

Generate dose-response curves by plotting percent viability or cytotoxicity against log-transformed compound concentration. Fit the data using nonlinear regression to calculate the half-maximal inhibitory concentration (IC₅₀) or half-maximal cytotoxic concentration (CC₅₀).

Quality Checks

Before interpreting results, perform the following quality checks:

Plate uniformity: Verify that vehicle control wells have consistent signals across the plate. A coefficient of variation (CV) greater than 15% indicates uneven cell seeding or edge effects.

Positive control response: Confirm that the positive control produces the expected level of cytotoxicity (typically >80% for LDH release or <20% viability for MTT/ATP). Failure indicates reagent degradation or assay interference.

Background signal: Ensure that background control wells have absorbance or luminescence values at least 10-fold lower than vehicle control wells. High background may indicate reagent contamination or compound interference.

Standard curve linearity: For ATP assays, verify that the cell number standard curve has an R² value >0.98. Nonlinearity indicates pipetting errors or ATP degradation.

Time course consistency: For kinetic studies, verify that vehicle control signals remain stable over the measurement period. A declining signal in controls indicates cell stress or nutrient depletion.

Result Interpretation

Interpretation of cytotoxicity assay results requires consideration of the specific endpoint measured. A compound that causes LDH release indicates membrane damage, typically associated with necrotic cell death. However, the absence of LDH release does not rule out cytotoxicity, because apoptotic cells may maintain membrane integrity until late stages. Conversely, a decrease in MTT reduction may indicate reduced metabolic activity without actual cell death, as occurs with cytostatic compounds or metabolic inhibitors.

ATP assays provide the most direct measure of viable cell number because ATP is rapidly degraded upon cell death. However, compounds that affect ATP synthesis (e.g., mitochondrial uncouplers) can cause false decreases in ATP levels without immediate cell death. Similarly, compounds that stimulate ATP production may give false increases.

When comparing results across assays, discrepancies often provide mechanistic insight. For example, a compound that reduces MTT signal without increasing LDH release may be cytostatic or apoptotic, while a compound that increases LDH release without affecting ATP levels may cause membrane damage without immediate metabolic collapse.

Troubleshooting

Limitations

Each cytotoxicity assay has inherent limitations that must be considered when designing experiments and interpreting results.

LDH assay limitations: The assay detects only membrane damage, missing early apoptotic events. Serum LDH in culture medium can elevate background, requiring serum-free conditions or careful background subtraction. Some compounds directly inhibit LDH or interfere with the coupled enzymatic reaction, producing false negatives or positives. The assay is less sensitive than ATP-based methods, requiring approximately 100–1,000 lysed cells for reliable detection.

MTT assay limitations: The assay measures metabolic activity rather than cell number, so compounds that affect mitochondrial function without causing cell death produce false results. MTT formazan crystals are insoluble and require solubilization, adding a step that can introduce variability. Reducing agents, including some antioxidants and thiol-containing compounds, can directly reduce MTT, producing false signals. The assay is not suitable for cells with low metabolic activity, such as primary hepatocytes or quiescent cells.

ATP assay limitations: ATP is unstable, requiring rapid processing and careful handling. The assay requires cell lysis, preventing time-course measurements from the same sample. Luciferase reagents are expensive compared to colorimetric reagents. Some compounds inhibit luciferase directly, producing false decreases in signal. The assay is highly sensitive, which can be a disadvantage when small numbers of dead cells contribute significant ATP from residual metabolic activity.

Documentation

Thorough documentation is essential for reproducibility and regulatory compliance. The following information should be recorded for each experiment:

Cell line information: Source, passage number, mycoplasma testing status, and culture conditions. For studies following ISO 10993-5 guidelines, documentation of cell line authentication is increasingly expected [2].

Test compound information: Chemical name, purity, source, lot number, solvent, and storage conditions. Prepare a stock solution record with preparation date and concentration.

Assay conditions: Cell seeding density, exposure duration, assay kit lot number and expiration date, plate reader settings, and incubation conditions.

Raw data: Plate maps, absorbance or luminescence values, and any data transformations. Store electronic files with appropriate backup.

Controls: Values for all controls, including vehicle, positive, negative, background, and maximum release controls. Document any control failures and corrective actions.

Calculations: Formulas used for percent viability or cytotoxicity, curve-fitting parameters, and IC₅₀ or CC₅₀ values with confidence intervals.

Deviations from protocol: Any modifications to standard procedures, including changes in incubation time, reagent concentrations, or plate format.

Biosafety Considerations

For BSL-1 routine work, standard microbiological practices apply as outlined in the Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition [3]. These include:

• Perform all cell culture work in a Class II biological safety cabinet.
• Decontaminate all liquid and solid waste containing cells or test compounds before disposal. Treat culture medium and supernatants with 10% bleach (final concentration) for at least 30 minutes before disposal.
• Use appropriate personal protective equipment: laboratory coat, gloves, and eye protection.
• Clean work surfaces with 70% ethanol or appropriate disinfectant before and after each procedure.
• Label all containers with cell lines, test compounds, and waste clearly.
• Maintain an inventory of cell lines and test compounds.

For work involving recombinant or synthetic nucleic acid molecules, follow the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [4]. This includes obtaining Institutional Biosafety Committee (IBC) approval for experiments involving genetically modified cells and documenting the biosafety level assigned to the work.

Frequently Asked Questions

Q1: Can I use the same cell lysate for both MTT and ATP assays? No. MTT requires live cells for the reduction reaction, while ATP assays require cell lysis. These assays are mutually exclusive on the same sample. However, you can perform parallel experiments on sister plates or use a multiplex approach where LDH release is measured from the supernatant, followed by an ATP assay on the remaining cells after washing.

Q2: Why does my MTT assay show increased signal at low compound concentrations? This phenomenon, known as hormesis, occurs when low doses of a compound stimulate cellular metabolism. Alternatively, the compound may directly reduce MTT, producing a false increase. To distinguish these possibilities, run a cell-free control with compound and MTT. If the signal persists, the compound is interfering with the assay.

Q3: How do I choose between LDH, MTT, and ATP assays for my experiment? Consider your experimental question first. If you need to distinguish necrotic from apoptotic cell death, use LDH in combination with an apoptosis-specific assay. If you are screening many compounds for general cytotoxicity, ATP assays offer the best sensitivity and throughput. If you are working with primary cells or cells with low metabolic activity, avoid MTT and use ATP or LDH.

Q4: What is the minimum number of cells required for each assay? For LDH, reliable detection requires approximately 100–1,000 lysed cells. For MTT, 1,000–10,000 viable cells are typically needed. For ATP, as few as 1–100 viable cells can be detected, making it the method of choice for low-cell-number applications such as primary cell cultures or 3D spheroids.

References and Further Reading

1. Ziemba B. Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models. 2025. PubMed ID: 41303685. Available at: https://pubmed.ncbi.nlm.nih.gov/41303685/

   • Provides an overview of the evolution from classical colorimetric assays to modern multiparametric and computational approaches in cytotoxicity testing.

2. Tenge K, Bhagwandas N, Bos A, de Vries R, Veldhuijzen van Zanten L. Towards standardizing cytotoxicity testing of 3D-printed orthodontic aligners and retainers: a scoping review. 2026. PubMed ID: 42334746. Available at: https://pubmed.ncbi.nlm.nih.gov/42334746/

   • Reviews variability in cytotoxicity testing practices and highlights the importance of standardized protocols following ISO 10993-5 and ISO 10993-12.

3. CDC and NIH. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition. U.S. Department of Health and Human Services, 2020. Available at: https://www.cdc.gov/labs/bmbl/index.html

   • Authoritative reference for biosafety principles, risk assessment, and containment practices in microbiological and biomedical laboratories.

4. National Institutes of Health. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. Available at: https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules/

   • Provides the institutional framework for biosafety oversight of research involving recombinant or synthetic nucleic acid molecules.

5. National Center for Biotechnology Information. NCBI Bookshelf: Molecular Biology and Laboratory Methods. Available at: https://www.ncbi.nlm.nih.gov/books/

   • Searchable collection of authoritative biomedical books and methods references for molecular biology and laboratory techniques.

Related Articles

• LDH Assay: Protocol for Measuring Cytotoxicity and Cell Viability
• Lowry Assay Protocol: Protein Quantification Method
• Kinase Activity Assay: Methods for Measuring Protein Kinase Activity
• Immunofluorescence Assay: Principles and Protocol for Protein Localization
• How to Calculate the Concentration of Protein Using the Lowry Assay
• Bradford Assay Protocol: Step-by-Step for Protein Quantification